Stories

Dan Primack Feb 14, 2017
SaveSave story

Private equity's role in the Marathon drug price debacle

Chris Potter / Flickr Creative Commons

I write a lot about financial engineering, a process through which private equity firms can juice returns without necessarily improving the underlying asset. But any negative connotations of such behavior pales in comparison to the profit engineering Chicago-based Valor Equity Partners has overseen, as a key investor in Marathon Pharmaceuticals, the Illinois-based drug company that tried to jack up prices on its Duchenne muscular dystrophy treatment to a whopping $89,000 (or an equally outrageous $54k after various rebates and discounts).